← Back to Clinical Trials
Recruiting NCT03932773

NCT03932773 Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03932773
Status Recruiting
Phase
Sponsor The University of Texas at Dallas
Condition Post Traumatic Stress Disorder
Study Type INTERVENTIONAL
Enrollment 330 participants
Start Date 2019-05-01
Primary Completion 2026-07-31

Trial Parameters

Condition Post Traumatic Stress Disorder
Sponsor The University of Texas at Dallas
Study Type INTERVENTIONAL
Phase N/A
Enrollment 330
Sex ALL
Min Age 18 Years
Max Age 60 Years
Start Date 2019-05-01
Completion 2026-07-31
Interventions
Active rTMSSham rTMSCognitive Processing Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to examine the benefits of combining repetitive Transcranial Magnetic Stimulation (rTMS) coupled with Cognitive Processing Therapy (CPT) in treating combat-related Posttraumatic Stress Disorder (PTSD) symptoms. The study will also examine change in depression, psychosocial functioning, and neurophysiological (i.e., electroencephalography and magnetic resonance images) measures.

Eligibility Criteria

Inclusion Criteria: * Veterans of Post-9/11 military conflicts * with diagnosis of PTSD based on CAPS-5 related to Post-9/11 military combat Exclusion Criteria: * current enrollment in an acute experimental treatment for PTSD or trauma-focused psychotherapy treatment * PTSD-inducing trauma exposure occurring within the last 3 months prior to pre-enrollment evaluation * history of epilepsy or seizure disorder, a history of major head trauma, * any neurologic condition likely to increase risk of seizures, * brain tumors, * moderate to severe substance use disorder in last 3 months or any substance use that puts the participant at increased risk or significant impairment * stroke, and blood vessel abnormalities in the brain, * dementia, * Parkinson's disease, Huntington's chorea, or multiple sclerosis * a high suicide risk * a lifetime history of psychotic disorder or bipolar disorder * inability to stop taking any medication that significantly lowers the seizure threshold * pregnant or n

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology